Literature DB >> 30144467

Intranasal oxytocin reduces weight gain in diet-induced obese prairie voles.

Adele M Seelke1, Maya A Rhine1, Konterri Khun1, Amira N Shweyk1, Alexandria M Scott1, Jessica M Bond1, James L Graham2, Peter J Havel2, Tami Wolden-Hanson3, Karen L Bales1, James E Blevins4.   

Abstract

Oxytocin (OT) elicits weight loss in diet-induced obese (DIO) rodents, nonhuman primates and humans by reducing food intake and increasing energy expenditure. In addition to being important in the regulation of energy balance, OT is involved in social behaviors including parent-infant bonds, friendships, and pair bonds. However, the impact of social context on susceptibility to diet-induced obesity (DIO) and feeding behavior (including food sharing) has not been investigated in a rodent model that forms strong social bonds (i.e. prairie vole). Our goals were to determine in Prairie voles (Microtus ochrogaster) whether i) social context impacts susceptibility to DIO and ii) chronic intranasal OT reverses DIO. Voles were housed in divided cages with holes in the divider and paired with a same-sex animal with either the same food [high fat diet (HFD)/HFD, [low fat diet (LFD; chow)/chow], or the opposite food (HFD/chow or chow/HFD) for 19 weeks. HFD-fed voles pair-housed with voles maintained on the HFD demonstrated increased weight relative to pair-housed voles that were both maintained on chow. The study was repeated to determine the impact of social context on DIO susceptibility and body composition when animals are maintained on purified sugar-sweetened HFD and LFD to enhance palatability. As before, we found that voles demonstrated higher weight gain on the HFD/HFD housing paradigm, in part, through increased energy intake and the weight gain was a consequence of an increase in fat mass. However, HFD-fed animals housed with LFD-fed animals (and vice versa) showed intermediate patterns of weight gain and evidence of food sharing. Of translational importance is the finding that chronic intranasal OT appeared to reduce weight gain in DIO voles through a decrease in fat mass with no reduction in lean body mass. These effects were associated with transient reductions in food intake and increased food sharing. These findings identify a role of social context in the pathogenesis of DIO and indicate that chronic intranasal OT treatment reduces weight gain and body fat mass in DIO prairie voles, in part, by reducing food intake. Published by Elsevier Inc.

Entities:  

Keywords:  (Microtus ochrogaster); Intranasal; Obesity; Oxytocin; Prairie vole

Mesh:

Substances:

Year:  2018        PMID: 30144467      PMCID: PMC6195438          DOI: 10.1016/j.physbeh.2018.08.007

Source DB:  PubMed          Journal:  Physiol Behav        ISSN: 0031-9384


  88 in total

1.  Fructose-fed rhesus monkeys: a nonhuman primate model of insulin resistance, metabolic syndrome, and type 2 diabetes.

Authors:  Andrew A Bremer; Kimber L Stanhope; James L Graham; Bethany P Cummings; Wenli Wang; Benjamin R Saville; Peter J Havel
Journal:  Clin Transl Sci       Date:  2011-08       Impact factor: 4.689

2.  Effects of central oxytocin administration on intraoral intake of glucose in deprived and nondeprived rats.

Authors:  C M Lokrantz; K Uvnäs-Moberg; J M Kaplan
Journal:  Physiol Behav       Date:  1997-08

3.  Early rearing experience is associated with vasopressin immunoreactivity but not reactivity to an acute non-social stressor in the prairie vole.

Authors:  Allison M Perkeybile; Karen L Bales
Journal:  Physiol Behav       Date:  2015-04-15

4.  Chronic hindbrain administration of oxytocin is sufficient to elicit weight loss in diet-induced obese rats.

Authors:  Zachary S Roberts; Tami Wolden-Hanson; Miles E Matsen; Vitaly Ryu; Cheryl H Vaughan; James L Graham; Peter J Havel; Daniel W Chukri; Michael W Schwartz; Gregory J Morton; James E Blevins
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2017-07-26       Impact factor: 3.619

5.  The CRF system mediates increased passive stress-coping behavior following the loss of a bonded partner in a monogamous rodent.

Authors:  Oliver J Bosch; Hemanth P Nair; Todd H Ahern; Inga D Neumann; Larry J Young
Journal:  Neuropsychopharmacology       Date:  2008-10-15       Impact factor: 7.853

6.  Oxytocin receptors are expressed on dopamine and glutamate neurons in the mouse ventral tegmental area that project to nucleus accumbens and other mesolimbic targets.

Authors:  Joanna Peris; Kaley MacFadyen; Justin A Smith; Annette D de Kloet; Lei Wang; Eric G Krause
Journal:  J Comp Neurol       Date:  2016-09-27       Impact factor: 3.215

7.  Hypothalamic proinflammatory lipid accumulation, inflammation, and insulin resistance in rats fed a high-fat diet.

Authors:  Kelly A Posey; Deborah J Clegg; Richard L Printz; Jaeman Byun; Gregory J Morton; Anuradha Vivekanandan-Giri; Subramaniam Pennathur; Denis G Baskin; Jay W Heinecke; Stephen C Woods; Michael W Schwartz; Kevin D Niswender
Journal:  Am J Physiol Endocrinol Metab       Date:  2008-12-30       Impact factor: 4.310

8.  Plasma and CSF oxytocin levels after intranasal and intravenous oxytocin in awake macaques.

Authors:  Sara M Freeman; Sridhar Samineni; Philip C Allen; Diane Stockinger; Karen L Bales; Granger G C Hwa; Jeffrey A Roberts
Journal:  Psychoneuroendocrinology       Date:  2016-01-18       Impact factor: 4.905

9.  Peripheral oxytocin treatment ameliorates obesity by reducing food intake and visceral fat mass.

Authors:  Yuko Maejima; Yusaku Iwasaki; Yui Yamahara; Misato Kodaira; Udval Sedbazar; Toshihiko Yada
Journal:  Aging (Albany NY)       Date:  2011-12       Impact factor: 5.682

10.  Oxytocin reduces caloric intake in men.

Authors:  Elizabeth A Lawson; Dean A Marengi; Rebecca L DeSanti; Tara M Holmes; David A Schoenfeld; Christiane J Tolley
Journal:  Obesity (Silver Spring)       Date:  2015-04-10       Impact factor: 5.002

View more
  7 in total

1.  Sex Differences and Estrous Influences on Oxytocin Control of Food Intake.

Authors:  Clarissa M Liu; Elizabeth A Davis; Andrea N Suarez; Ruth I Wood; Emily E Noble; Scott E Kanoski
Journal:  Neuroscience       Date:  2019-11-15       Impact factor: 3.590

Review 2.  Regulation of Metabolic Health by an "Olfactory-Hypothalamic Axis" and Its Possible Implications for the Development of Therapeutic Approaches for Obesity and T2D.

Authors:  Mara Alaide Guzmán-Ruiz; Adriana Jiménez; Alfredo Cárdenas-Rivera; Natalí N Guerrero-Vargas; Diana Organista-Juárez; Rosalinda Guevara-Guzmán
Journal:  Cell Mol Neurobiol       Date:  2021-04-04       Impact factor: 5.046

3.  Hindbrain Administration of Oxytocin Reduces Food Intake, Weight Gain and Activates Catecholamine Neurons in the Hindbrain Nucleus of the Solitary Tract in Rats.

Authors:  Vishwanath T Anekonda; Benjamin W Thompson; Jacqueline M Ho; Zachary S Roberts; Melise M Edwards; Ha K Nguyen; Andrew D Dodson; Tami Wolden-Hanson; Daniel W Chukri; Adam J Herbertson; James L Graham; Peter J Havel; Tomasz A Wietecha; Kevin D O'Brien; James E Blevins
Journal:  J Clin Med       Date:  2021-10-29       Impact factor: 4.241

Review 4.  The role of oxytocin in regulation of appetitive behaviour, body weight and glucose homeostasis.

Authors:  Elizabeth A Lawson; Pawel K Olszewski; Aron Weller; James E Blevins
Journal:  J Neuroendocrinol       Date:  2019-11-28       Impact factor: 3.627

5.  A Neuroscientist's Guide to the Vole.

Authors:  William M Kenkel; Morgan L Gustison; Annaliese K Beery
Journal:  Curr Protoc       Date:  2021-06

Review 6.  Oxytocin as an Anti-obesity Treatment.

Authors:  JingJing Niu; Jenny Tong; James E Blevins
Journal:  Front Neurosci       Date:  2021-10-13       Impact factor: 4.677

7.  Effects of Combined Oxytocin and Beta-3 Receptor Agonist (CL 316243) Treatment on Body Weight and Adiposity in Male Diet-Induced Obese Rats.

Authors:  Melise M Edwards; Ha K Nguyen; Andrew D Dodson; Adam J Herbertson; Tomasz A Wietecha; Tami Wolden-Hanson; James L Graham; Mackenzie K Honeycutt; Jared D Slattery; Kevin D O'Brien; Peter J Havel; James E Blevins
Journal:  Front Physiol       Date:  2021-09-08       Impact factor: 4.566

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.